EGFR is overexpressed in the majority of patients with squamous cell anal carcinoma^4,5 and is likely linked to tumor-genesis and progression in anal cancer.⁵

EGFR overexpression in bladder cancer is reported to be between 27% and 86%.⁶

EGFR is overexpressed in up to 14% of breast tumors, with a higher incidence in hereditary breast cancer.⁷ In patients who have TNBC, overexpression of EGFR is associated with increased metastasis and poor prognosis.^7,2

Up to 91% of patients with advanced cervical cancers overexpress EGFR. Significantly higher EGFR overexpression is reported in tumor size >4 cm and ulcerative lesions.⁸

EGFR is overexpressed in approximately 60%-80% of colorectal tumors. It is associated with poor prognosis.⁹

EGFR overexpression in endometrial cancer is linked to a decrease in disease-free and overall survival.¹⁰ It is overexpressed in up to 67% of cases.¹¹

EGFR expression in esophageal squamous cell carcinoma and esophageal and esophagogastric junction adenocarcinoma is associated with worse prognosis and may be used to predict outcomes.^12,13

Overexpression of EGFR in gastric tumors is reported in 27%-64% of patients but its prognostic value is unknown.¹⁴

Primary glioblastomas have a higher incidence of EGFR gene amplification (40%) and EGFR overexpression (>60%) compared to secondary glioblastoma (8% and 10%, respectively). EGFR amplification becomes more common as a patient gets older.¹⁵

The majority of people with squamous cell carcinoma of the head and neck overexpress EGFR,¹⁶ and is tied to poor prognosis.¹⁷

EGFR is expressed in >60% of Non–Small-cell lung carcinomas¹⁸ and is associated with reduced survival, lymph node metastasis, and poor chemosensitivity.¹⁹

In advanced epithelial ovarian carcinoma, EGFR is over expressed in 55% to 98% of patients.²⁰